

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/821,832		ATTY. DOCKET NO.: W0571.70010US02	
				FILING DATE: March 30, 2001		CONFIRMATION NO.: 6240	
				APPLICANT: Tuschl et al.			
				GROUP ART UNIT: 1635		EXAMINER: L. V. Wollenberger	
Sheet	1	of	2				

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		6,001,990		Wands et al.	12/1999
		5,998,203		Matulic-Adamic et al.	12/1999
		5,814,500		Dietz	09/1998
		5,514,577		Draper et al.	05/1996
		2007/0093445		Tuschl et al.	04/2007
		2006/0084621	A1	Vornlocher	04/20/2006
		2005/0100907	A1	Kreutzer et al.	05/12/2005
		2004/0053875		Kreutzer et al.	03/2004
		2002/0114784		Li et al.	08/22/2002

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		WO	94/15645		Denner et al.	07/1994	
		WO	00/44895		Kreutzer	09/17/2001	N

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		ALFONZO et al., "The mechanism of U insertion/deletion RNA editing in kinetoplastid mitochondria, 1997, Nucleic Acids Research, Vol. 25, No. 19, pgs. 3751-3759	
		AOKI et al., "Inhibition of the p53 Tumor Suppressor Gene Results in Growth of Human Aortic Vascular Smooth Muscle Cells," 1999, Hypertension, Vol. 34, No. 2, pgs. 192-200	
		BAEV et al., "Stress-Induced Membrane Association of the Streptococcus mutans GTP-Binding Protein, an Essential G Protein, and Investigation of Its Physiological Role by Utilizing an Antisense RNA Strategy," 1999, Infection and Immunity, Vol. 67, pgs. 4510-16	
		ELBASHIR et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," 2002, Methods 26, pgs. 199-213	

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/821,832	ATTY. DOCKET NO.: W0571.70010US02
				FILING DATE: March 30, 2001	CONFIRMATION NO.: 6240
				APPLICANT: Tuschl et al.	
				GROUP ART UNIT: 1635	EXAMINER: L. V. Wollenberger
Sheet	2	of	2		

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		KENNERDELL and CARTEW, "Heritable gene silencing in Drosophila using double-stranded RNA," 2000, Nature Biotechnology, 17:896-898*	
		MORITA et al., "Antisense oligonucleotides targeting c-fos mRNA inhibit rheumatoid synovial fibroblast proliferation," 1998, Ann Rheum Dis, Vol. 57, pgs 122-124	
		PARK et al., "Double-stranded siRNA targeted to the huntingtin gene does not induce DNA methylation, 2004, Biochemical and Biophysical Research Communications, Vol. 323, pages 275-280	
		PFEFFER et al., "RNA silencing," B.I.F. Fugura, 2005, Vol. 20, pgs. 83-91	
		SCHERER et al., "Approaches for the sequence-specific knockdown of mRNA," 2003, Nat. Biotechnol., pgs. 1457-1465, vol. 21, no. 12**	
		TUSCHL, "Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy," Molecular Interventions, 2002, Vol. 2, no. 3, pgs. 158-167	
		VINAYAK et al., "Chemical Synthesis of RNA using Fast Oligonucleotide Deprotection Chemistry," Database Biosis Online, Biosciences Information Service, Philadelphia, PA US: 1992, Database Accession No. PREV199294000583, XP-02247596	
		ZHANG et al., "Targeted gene silencing by small interfering RNA-based knock-down technology," 2004, Current Pharmaceutical Biotechnology, vol. 5, p. 1-7**	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a co-pending application, Serial No. 11/880,464, filed 07/19/07.

**a copy of this reference is not provided as it was previously cited by or submitted to the office in a co-pending application, Serial No. 10/255,568, filed 09/26/02.

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]